Will Shire's acute HAE drug OK shift dynamic for ViroPharma's prophylactic?
This article was originally published in Scrip
The US FDA's approval on 25 August of Shire's hereditary angioedema (HAE) drug Firazyr (icatibant) as the first and only self-administered subcutaneous treatment for acute attacks has not only opened the gate for the medicine to claim a favourable chunk of the US market in that indication, but also could have an impact on the prophylactic setting.
You may also be interested in...
Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.